Loading…
← CockpitCompetitor Analysis › 115180.KS Qurient Co., Ltd.Open in the cockpit ↗

Qurient Co., Ltd.115180.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Biotechnology
Momentum laggard 5
Mkt cap
$452M
US dollars, full cap
Free float
79%
of shares outstanding
$/day
$1.72M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-187.4 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · KRW₩13,030
1D-0.9%
1W-17.6%
1M-34.9%
3M-49.1%
6M-56.5%
YTD-56.9%
1Y-36.9%
ATR %11.9%
52w lowhigh79.3% off high

What Qurient does

Employees: 32

Qurient at a glance

Size Qurient (115180.KS) is a South Korea Health Care company (Biotechnology) with a market value of $452M, the 372nd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩13,030 on 18 Nov 2026.

Performance Over six months the shares fell 56.5%, against -1.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue fell 13.8% over the last twelve months (peer median +5.0%); the operating margin is -511.6% (peer median -4.1%).

Valuation It trades at 84.4× enterprise value to sales against a peer median of 6.4× (2nd most expensive of 14).

Capital Return on invested capital runs 187.4 points below its cost of capital (5.6% WACC).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 101115180.KS 47
Six months, rebased to 100: Qurient against the median of its 20 peers (local-currency closes).

Qurient financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩7.13B₩6.98B₩9.18B₩9.03B₩8.47B
Revenue growth—-24%+2%+7%—
Gross profit-₩751M-₩31.4M₩496M₩944M₩1.06B
EBITDA-₩35.0B-₩28.5B-₩26.6B-₩22.4B-₩26.8B
Net income-₩38.7B-₩30.1B-₩23.6B-₩21.1B-₩25.5B
Free cash flow-₩36.3B-₩27.5B-₩22.1Bn/a-₩24.2B
Capital expenditure₩158M₩3.70B₩83.7M₩101M₩519M
Total debt₩1.00B₩12.7B₩841M₩334M₩807M

Quarterly statements and history in the cockpit →

Qurient competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%041960STTK6589ARVNDMACIRLA000710KMDA6037391789FENC41476547115180.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Qurient is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×25×50×75×0419606589000710KMDAFENCPRTA250941476547115180.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qurient is the large dot.

Qurient competitors and peer comparison

How Qurient compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qurient against its 20 peers (data as of 18 Nov 2026)
Measure115180.KSPeer medianRank in peer set
1-month return-34.9%-7.3%lowest of 21
6-month return-56.5%-1.8%lowest of 19
Distance from 52-week high-79.3%-37.5%2nd lowest of 21
Revenue growth (TTM)-13.8%+5.0%3rd lowest of 16
Operating margin-511.6%-4.1%2nd lowest of 15
EV / Sales84.4×6.4×2nd most expensive of 14
ROIC minus cost of capital-187.4 pp-6.0 pplowest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a

Questions

Which companies are Qurient's closest peers?
The cockpit's peer set: Komipharm International (041960.KS), Shattuck Labs (STTK), EirGenix (6589.TW), Arvinas (ARVN), HanchorBio (7827.TW), DiaMedica Therapeutics (DMAC), IRulya Therapeutics (IRLA), Berry Genomics (000710.SZ).
Is Qurient expensive compared with its peers?
On ev / sales it trades at 84.4× against a peer median of 6.4×, 2nd most expensive of 14 in its peer set.
How has Qurient stock performed?
Over six months to 18 Nov 2026 the shares returned -56.5% against -1.8% for the median peer; over one year -36.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.